CSL Limited logo

CSL Limited (CSJ)

Market Closed
10 Jun, 06:03
XFRA XFRA
61. 42
+0.42
+0.6885%
- Market Cap
- P/E Ratio
2.7% Div Yield
100 Volume
- Eps
61
Previous Close
Add Transaction
Day Range
61.42 61.42
Year Range
56 153.06
Want to track CSJ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

CSJ closed Wednesday higher at €61.42, an increase of 0.6885% from Tuesday's close, completing a monthly increase of 6.9476% or €3.99. Over the past 12 months, CSJ stock lost -37.9533%.
CSJ pays dividends to its shareholders, with the most recent payment made on Apr 09, 2026. The next estimated payment will be in In 3 months on Oct 09, 2026 for a total of €1.81856.
The last earnings report, released on Feb 10, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
CSL Limited has completed 1 stock splits, with the recent split occurring on Oct 18, 2007.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on ASX (AUD).

CSJ Chart

CSL Limited (CSJ) FAQ

What is the stock price today?

The current price is €61.42.

On which exchange is it traded?

CSL Limited is listed on XFRA.

What is its stock symbol?

The ticker symbol is CSJ.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 2.7%.

What is its market cap?

As of today, no market cap data is available.

Has CSL Limited ever had a stock split?

CSL Limited had 1 splits and the recent split was on Oct 18, 2007.

CSL Limited Profile

Biotechnology Industry
Healthcare Sector
Gordon Naylor DipCompSc CEO
XFRA Exchange
AU000000CSL8 ISIN
AU Country
32,698 Employees
10 Mar 2026 Last Dividend
18 Oct 2007 Last Split
- IPO Date

Overview

CSL Limited is a globally prominent biopharmaceutical and vaccine company with its roots firmly planted in Melbourne, Australia since 1916. The company has carved out a significant presence not only in its home country but also across vital markets in the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and beyond. CSL Limited operates with a strategic focus on research, development, manufacturing, marketing, and distribution of innovative biopharmaceutical and vaccine solutions. It is organized into three main segments: CSL Behring, CSL Seqirus, and CSL Vifor, each targeting specific healthcare needs worldwide. Additionally, CSL Limited actively engages in licensing its intellectual property, underscoring its contributions to advancing global healthcare technologies and treatments.

Products and Services

  • CSL Behring

    This segment caters to a variety of healthcare needs through its diverse portfolio of products. CSL Behring is renowned for its plasma products, contributing to therapies for immunodeficiencies and rare diseases. It also pioneers in gene therapies, offering cutting-edge treatments for genetic disorders. Furthermore, CSL Behring provides recombinant products, marking significant advances in biotechnology for therapeutic uses.

  • CSL Seqirus

    Specializing in influenza-related products, CSL Seqirus stands out for its proactive approach towards flu prevention and pandemic preparedness. It offers a breadth of seasonal flu vaccines, ensuring public health safety across the globe. Additionally, CSL Seqirus collaborates with governments worldwide, offering pandemic services and solutions aimed at combating influenza outbreaks efficiently and effectively.

  • CSL Vifor

    With a keen focus on iron deficiency and nephrology, the CSL Vifor segment advances medical treatments in these crucial therapeutic areas. By developing and distributing specialized products, CSL Vifor addresses a range of conditions related to kidney health and iron metabolism, providing essential solutions for patients suffering from these ailments.

Contact Information

Address: 45 Poplar Road
Phone: 61 3 9389 1911